Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral QLT091001 in inherited retinal disease due to RPE65 or LRAT mutations
2013-005393-22Phase 3Terminated
- Sponsor
- QLT Inc.
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zuretinol in Fundus dystrophy, Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), sponsored by QLT Inc. Primary endpoint: Percent change from baseline in visual field volume in the study eye. Started Sep 2016; status: terminated.
02
Drugs
zuretinol
03
Conditions
Fundus dystrophyLeber congenital amaurosis (LCA)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2013-005393-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005393-22.